DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong ...
Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...
The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version. In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some ...
One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) announced new AI-enabled features ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results